Prognostic value of PSA Kinetic Ratio in high-volume mCSPC patients treated with abiraterone or enzalutamide: a single-center retrospective study

Abstract Background The use of androgen receptor pathway inhibitors (ARPIs), such as abiraterone and enzalutamide, in combination with androgen deprivation therapy (ADT), has significantly enhanced outcomes in metastatic castration-sensitive prostate cancer (mCSPC). However, validated early prognost...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Sila Oksuz, Oguzcan Kınıkoglu, Nisanur Sariyar, Mert Ozdemir, Deniz Isik, Heves Surmeli, Seval Ay, Hatice Odabas, Nedim Turan
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2026-04-01
coleção:	BMC Cancer
Assuntos:	Androgen receptor pathway inhibitors Kinetic ratio PSA kinetics
Acesso em linha:	https://doi.org/10.1186/s12885-026-16037-8
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!